31-45 of 74
James M. Cleary, MD, PhD
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
MinuteCE®Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
CME/CEChairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
- advertisement
Daniel Gaudet, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
MinuteCE®Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
APOC3 Inhibition: A Novel Approach to Lowering TGs
MinuteCE®APOC3 Inhibition: A Novel Approach to Lowering TGs
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Latest Clinical Trial Outcomes and Breakthroughs for FCS
MinuteCE®Latest Clinical Trial Outcomes and Breakthroughs for FCS
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
- advertisement
SHTG: Decoding the Latest Clinical Trial Outcomes
MinuteCE®SHTG: Decoding the Latest Clinical Trial Outcomes
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Remnant Cholesterol: The Missing Link in ASCVD risk
MinuteCE®Remnant Cholesterol: The Missing Link in ASCVD risk
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
MinuteCE®Targeting Mixed Hyperlipidemia with APOC3 Inhibition
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
